Cargando…
Repurposed Drugs in Gastric Cancer
Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC tr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822219/ https://www.ncbi.nlm.nih.gov/pubmed/36615513 http://dx.doi.org/10.3390/molecules28010319 |
_version_ | 1784865892071374848 |
---|---|
author | Araújo, Diana Ribeiro, Eduarda Amorim, Irina Vale, Nuno |
author_facet | Araújo, Diana Ribeiro, Eduarda Amorim, Irina Vale, Nuno |
author_sort | Araújo, Diana |
collection | PubMed |
description | Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease. |
format | Online Article Text |
id | pubmed-9822219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98222192023-01-07 Repurposed Drugs in Gastric Cancer Araújo, Diana Ribeiro, Eduarda Amorim, Irina Vale, Nuno Molecules Review Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease. MDPI 2022-12-30 /pmc/articles/PMC9822219/ /pubmed/36615513 http://dx.doi.org/10.3390/molecules28010319 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Araújo, Diana Ribeiro, Eduarda Amorim, Irina Vale, Nuno Repurposed Drugs in Gastric Cancer |
title | Repurposed Drugs in Gastric Cancer |
title_full | Repurposed Drugs in Gastric Cancer |
title_fullStr | Repurposed Drugs in Gastric Cancer |
title_full_unstemmed | Repurposed Drugs in Gastric Cancer |
title_short | Repurposed Drugs in Gastric Cancer |
title_sort | repurposed drugs in gastric cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822219/ https://www.ncbi.nlm.nih.gov/pubmed/36615513 http://dx.doi.org/10.3390/molecules28010319 |
work_keys_str_mv | AT araujodiana repurposeddrugsingastriccancer AT ribeiroeduarda repurposeddrugsingastriccancer AT amorimirina repurposeddrugsingastriccancer AT valenuno repurposeddrugsingastriccancer |